[PDF][PDF] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of …
MJ Moore, D Goldstein, J Hamm, A Figer… - Journal of clinical …, 2007 - Citeseer
MJ Moore, D Goldstein, J Hamm, A Figer, JR Hecht, S Gallinger, HJ Au, P Murawa, D Walde…
Journal of clinical oncology, 2007•CiteseerPurpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic
tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and
this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-
targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or
metastatic pancreatic cancer.
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic
tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and
this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-
targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or
metastatic pancreatic cancer.
Purpose
Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.
Citeseer